RNASET2 and ovarian carcinoma: Conversely, FBXO6 overexpression led to a marked decrease in RNASET2 protein expression in a dose-dependent manner, clearly suggesting that FBXO6 is involved in the degradation of RNASET2 protein in both ovarian cancer cell models.